

NCCN Guidelines® Insights

Lung Cancer Screening, Version 1.2015

Featured Updates to the NCCN Guidelines

Douglas E. Wood, MD^{1,*}; Ella Kazerooni, MD^{2,*}; Scott L. Baum, MD³; Mark T. Dransfield, MD⁴; George A. Eapen, MD⁵; David S. Ettinger, MD⁶; Lifang Hou, MD, PhD⁷; David M. Jackman, MD⁸; Donald Klippenstein, MD⁹; Rohit Kumar, MD¹⁰; Rudy P. Lackner, MD¹¹; Lorriana E. Leard, MD¹²; Ann N.C. Leung, MD¹³; Samir S. Makani, MD¹⁴; Pierre P. Massion, MD¹⁵; Bryan F. Meyers, MD, MPH¹⁶; Gregory A. Otterson, MD¹⁷; Kimberly Peairs, MD⁶; Sudhakar Pipavath, MD¹; Christie Pratt-Pozo, MA, DHS⁹; Chakravarthy Reddy, MD¹⁸; Mary E. Reid, PhD¹⁹; Arnold J. Rotter, MD²⁰; Peter B. Sachs, MD²¹; Matthew B. Schabath, PhD⁹; Lecia V. Sequist, MD, MPH²²; Betty C. Tong, MD, MHS²³; William D. Travis, MD²⁴; Stephen C. Yang, MD⁶; Kristina M. Gregory, RN, MSN, OCN^{25,*}; and Miranda Hughes, PhD^{25,*}

Abstract

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening provide recommendations for selecting individuals for lung cancer screening, and for evaluation and follow-up of nodules found during screening, and are intended to assist with clinical and shared decision-making. These NCCN Guidelines Insights focus on the major updates to the 2015 NCCN Guidelines for Lung Cancer Screening, which include a revision to the recommendation from category 2B to 2A for one of the high-risk groups eligible for lung cancer screening. For low-dose CT of the lung, the recommended slice width was revised in the table on "Low-Dose Computed Tomography Acquisition, Storage, Interpretation, and Nodule Reporting." (J Natl Compr Canc Netw 2015;13:23–34)

From ¹University of Washington/Seattle Cancer Care Alliance; ²University of Michigan Comprehensive Cancer Center; ³St. Jude Children's Research Hospital/The University of Tennessee Health Science Center; ⁴University of Alabama at Birmingham Comprehensive Cancer Center; ⁵The University of Texas MD Anderson Cancer Center; ⁶The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; ⁷Robert H. Lurie Comprehensive Cancer Center of Northwestern University; ⁸Dana-Farber/Brigham and Women's Cancer Center; ⁹Moffitt Cancer Center; ¹⁰Fox Chase Cancer Center; ¹¹Fred & Pamela Buffett Cancer Center at The Nebraska Medical Center; ¹²UCSF Helen Diller Family Comprehensive Cancer Center; ¹³Stanford Comprehensive Cancer Center; ¹⁴UC San Diego Moores Cancer Center; ¹⁵Vanderbilt-Ingram Cancer Center; ¹⁶Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine; ¹⁷The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute; ¹⁸Huntsman Cancer Institute at the University of Utah; ¹⁹Roswell Park Cancer Institute; ²⁰City of Hope Comprehensive Cancer Center; ²¹University of Colorado Cancer Center; ²²Massachusetts General Hospital Cancer Center; ²³Duke Cancer Institute; ²⁴Memorial Sloan Kettering Cancer Center; and ²⁵National Comprehensive Cancer Network.

*Provided content development and/or authorship assistance.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. **The NCCN Guidelines® Insights highlight important changes to the NCCN Guidelines® recommendations from previous versions. Colored markings in the algorithm show changes and the discussion aims to further the understanding of these changes by summarizing salient portions of the NCCN Guideline Panel discussion, including the literature reviewed.**

These NCCN Guidelines Insights do not represent the full NCCN Guidelines; further, the National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding the content, use, or application of the NCCN Guidelines and NCCN Guidelines Insights and disclaims any responsibility for their applications or use in any way.

The full and most current version of these NCCN Guidelines are available at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2015, All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Lung Cancer Screening, Version 1.2015

NCCN: Continuing Education**Accreditation Statement**

This activity is designated to meet the educational needs of physicians, nurses, and pharmacists involved in the management of patients with cancer. There is no fee for this article. The National Comprehensive Cancer Network (NCCN) is accredited by the ACCME to provide continuing medical education for physicians. NCCN designates this journal-based CE activity for a maximum of 1.0 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NCCN is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.

NCCN designates this educational activity for a maximum of 1.0 contact hour. Accreditation as a provider refers to recognition of educational activities only; accredited status does not imply endorsement by NCCN or ANCC of any commercial products discussed/displayed in conjunction with the educational activity. Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.



National Comprehensive Cancer Network is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. NCCN designates this continuing education activity for 1.0 contact hour(s) (0.1 CEUs) of continuing education credit in states that recognize ACPE accredited providers. This is a knowledge-based activity. UAN: 0836-0000-15-002-H01-P

All clinicians completing this activity will be issued a certificate of participation. To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at <http://education.nccn.org/node/59435>; and 4) view/print certificate.

Release date: January 1, 2015; Expiration date: January 1, 2016

Learning Objectives:

Upon completion of this activity, participants will be able to:

- Integrate into professional practice the updates to NCCN Guidelines for Lung Cancer Screening
- Describe the rationale behind the decision-making process for developing the NCCN Guidelines for Lung Cancer Screening

Disclosure of Relevant Financial Relationships**Editor:**

Kerrin M. Green, MA, Assistant Managing Editor, *JNCCN—Journal of the National Comprehensive Cancer Network*, has disclosed that she has no relevant financial relationships.

CE Authors:

Deborah J. Moonan, RN, BSN, Director, Continuing Education, NCCN, has disclosed that she has no relevant financial relationships.

Ann Gianola, MA, Manager, Continuing Education Accreditation & Program Operations, NCCN, has disclosed that she has no relevant financial relationships.

Kristina M. Gregory, RN, MSN, OCN, Vice President, Clinical Information Operations, NCCN, has disclosed that she has no relevant financial relationships.

Rashmi Kumar, PhD, Senior Manager, Clinical Content, NCCN, has disclosed that she has no relevant financial relationships.

Individuals Who Provided Content Development and/or Authorship Assistance:


Douglas E. Wood, MD, Panel Chair, has disclosed the following relationships with commercial interests: Consultant fees/honoraria and grant/research support from Spiration, Inc.

Ella Kazerooni, MD, Panel Vice-Chair, has disclosed that she has no relevant financial relationships.

Miranda Hughes, PhD, Oncology Scientist/Senior Medical Writer, NCCN, has disclosed that she has no relevant financial relationships.

Supported by an educational grant from Eisai; a contribution from Exelixis Inc.; educational grants from Genentech BioOncology, Merck, Novartis Oncology, Novocure; and by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.

Lung Cancer Screening, Version 1.2015



^aIt is recommended that institutions performing lung cancer screening use a multidisciplinary approach that includes the specialties of thoracic radiology, pulmonary medicine, and thoracic surgery.

^bLung cancer screening is appropriate to consider for high-risk patients who are potential candidates for definitive treatment. Chest x-ray is not recommended for lung cancer screening.

^cAll current smokers should be advised to quit smoking, and former smokers should be advised to remain abstinent from smoking (<http://www.surgeongeneral.gov/initiatives/tobacco/index.html>). For additional cessation support and resources, smokers can be referred to <http://www.smokefree.gov>. Lung cancer screening should not be considered a substitute for smoking cessation.

^dDocumented high radon exposure.

^eAgents that are identified specifically as carcinogens targeting the lungs: silica, cadmium, asbestos, arsenic, beryllium, chromium, diesel fumes, nickel, coal smoke, and soot.

^fThere is increased risk of developing new primary lung cancer among survivors of lung cancer, lymphomas, cancers of the head and neck, or smoking-related cancers.

^gIndividuals exposed to second-hand smoke have a highly variable exposure to the carcinogens, with varying evidence for increased risk after this variable exposure. Therefore, second-hand smoke is not independently considered a risk factor for lung cancer screening.

Version 1.2015 © National Comprehensive Cancer Network, Inc. 2014. All rights reserved. The NCCN Guidelines[®] and this illustration may not be reproduced in any form without the express written permission of NCCN[®].

LCS-1

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Overview

Lung cancer is the leading cause of cancer-related mortality in the United States and worldwide.¹⁻⁴ In 2014, it was estimated that 159,260 deaths (86,930 in men; 72,330 in women) from lung cancer would occur in the United States.¹ Currently, most lung cancer is diagnosed clinically when patients present with symptoms such as persistent cough, chest pain, and weight loss; unfortunately, patients with these symptoms usually have advanced lung cancer. Not surprisingly, the 5-year survival rate is only 16.8%.^{5,6} Early detection of lung cancer is an important opportunity for decreasing mortality. Data support using low-dose computed tomography (LDCT) to screen individuals at high risk for lung cancer.⁷⁻¹¹ Chest radiograph is not recommended for lung cancer screening.^{11,12}

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Lung Cancer Screening were developed in 2011 and have been

Lung Cancer Screening, Version 1.2015

Low-Dose Computed Tomography Acquisition, Storage, Interpretation, and Nodule Reporting

Acquisition	Small Patient (BMI ≤30)	Large Patient (BMI >30)
Total radiation exposure	≤3 mSv	≤5 mSv
kVp	100-120	120
mAs	≤40	≤60
All Patients		
Gantry rotation speed	≤0.5	
Detector collimation	≤1.5 mm	
Slice width	≤2.5 mm; ≤1.0 mm preferred	
Slice interval	≤slice width; 50% overlap preferred for 3D and CAD applications	
Scan acquisition time	≤10 seconds (single breath hold)	
Breathing	Maximum inspiration	
Contrast	No oral or intravenous contrast	
CT scanner detectors	≥16	
Storage	All acquired images, including thin sections; MIPs and CAD renderings if used	
Interpretation Tools		
Platform	Computer workstation review	
Image type	Standard and MIP images	
Comparison studies	Comparison with prior chest CT images (not reports) is essential to evaluate change in size, morphology, and density of nodules; review of serial chest CT exams is important to detect slow growth	
Nodule Parameters		
Size	Largest mean diameter on a single image*	
Density	Solid, ground-glass, or mixed†	
Calcification	Present/absent; if present: solid, central vs. eccentric, concentric rings, popcorn, stippled, amorphous	
Fat	Report if present	
Shape	Round/ovoid, triangular	
Margin	Smooth, lobulated, spiculated	
Lung location	By lobe of the lung, preferably by segment, and if subpleural	
Location in dataset	Specify series and image number for future comparison	
Temporal comparison	If unchanged, include the longest duration of no change as directly viewed by the interpreter on the images (not by report); if changed, report current and prior size	

BMI = body mass index; CAD = computer-aided diagnosis; CT = computed tomography; MIP = maximum intensity projection.

*Mean of the longest diameter of the nodule and its perpendicular diameter, when compared to the baseline scan.

†Mixed; otherwise referred to as part solid.

Version 1.2015 © National Comprehensive Cancer Network, Inc. 2014. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

LCS-A

updated every year.^{11,13,14} These guidelines (1) describe risk factors for lung cancer; (2) recommend criteria for selecting high-risk individuals for screening; (3) provide recommendations for evaluation and follow-up of nodules found during screening; (4) discuss the accuracy of LDCT screening protocols and imaging modalities; and (5) discuss the benefits and risks of screening. Updates to the 2015 version of these guidelines include a revision to the recommendation from category 2B to 2A for one of the high-risk groups eligible for lung cancer screening (see LCS-1, page 25, and “Selection of Individuals for Lung Screening Based on High-Risk Status,” page 27; to view the complete and most recent version of these guidelines, visit NCCN.org).¹⁵ Furthermore, for LDCT of the lung, the recommended slice width was revised (see LCS-A, above, and “Management of Nodules Found on LDCT,” page 29).¹⁶

Tobacco smoking is a major modifiable risk factor in the development of lung cancer and accounts

for most lung cancer–related deaths.^{2,17} Smoking tobacco is also associated with other cancers and diseases, and an estimated 443,000 adults in the United States die from smoking-related illnesses each year.¹⁸ Tobacco smoke contains more than 7000 compounds, of which more than 50 are known carcinogens.^{19–21} The risk of developing lung cancer from smoking tobacco has been firmly established, with the relative risk for lung cancer being approximately 20-fold higher^{2,22} for smokers than for nonsmokers. Cessation of tobacco smoking decreases the risk for lung cancer.^{23–26} However, even former smokers have a higher risk for lung cancer than never-smokers. Lung cancer screening is not a substitute for smoking cessation. Smokers, including those undergoing lung cancer screening, should always be encouraged to quit smoking tobacco (<http://www.smokefree.gov/>),^{27,28} and former smokers should be encouraged to remain abstinent. Programs using behavioral counseling combined with FDA-approved medica-

Lung Cancer Screening, Version 1.2015

tions that promote smoking cessation can be very useful in helping individuals to quit.^{29,30}

Randomized Trials for Lung Screening

Disease-specific mortality, which is the number of cancer deaths relative to the number of individuals screened, is considered the ultimate test of screening effectiveness and is the only metric without bias.³¹ Randomized controlled screening trials are essential for determining whether cancer screening decreases disease-specific mortality. Nonrandomized trials are subject to biases that may cause an apparent increase in survival.³² Multiple randomized trials are assessing LDCT screening for lung cancer among high-risk groups, including the National Lung Screening Trial (NLST), sponsored by the NCI³³; the Dutch-Belgian randomized trial (NELSON); and the UK Lung Cancer Screening Trial (UKLS).^{7,34-40} Results from the NLST show that LDCT decreased the risk of death from lung cancer by 20% (95% CI, 6.8–26.7; $P=.004$) in high-risk smokers compared with chest radiography alone,¹¹ and that to prevent 1 lung cancer death, it is necessary to screen 320 high-risk individuals. Although the NLST also reported a 7% decrease in all-cause mortality, the apparent decrease was not significant after lung cancer mortality had been subtracted.

Lung Cancer Screening Guidelines

NCCN was the first major organization to develop lung cancer screening guidelines using LDCT based on the NLST data.¹³ The US Preventive Services Task Force (USPSTF) recommends lung screening for 55- to 80-year-old individuals with a 30 pack-year or more history of smoking who are either current or former smokers who quit within the last 15 years. Their grade B recommendation means that lung screening is required to be covered by private payers as an essential health benefit without copay under the Affordable Care Act beginning in January 2015.⁴¹ In November 2014, the Centers for Medicare & Medicaid Services (CMS) released their draft coverage decision to pay for lung cancer screening in 55- to 74-year-old individuals with the same smoking history used by the USPSTF, with requirements such as documented shared decision-making and participation in a clinical registry.

The final decision will be posted in February 2015.⁴²⁻⁴⁴ The cost-effectiveness of lung screening with LDCT was calculated for the NLST study.⁴⁵

Estimates are that lung screening with LDCT will cost \$81,000 per quality-adjusted life-year (QALY) gained and \$52,000 per life-year gained, which is less than a threshold level of \$100,000 per QALY gained that some experts consider to be a reasonable value in the United States. Guidelines published before the CISNET (Cancer Intervention and Surveillance Modeling Network) modeling studies used by the USPSTF, including those from the American College of Chest Physicians and ASCO, recommend lung cancer screening for individuals who meet the high-risk criteria of the NLST (ie, smokers and former smokers at high risk based on age and smoking history [ages 55–74 years with a ≥ 30 pack-year smoking history]).⁴⁶ Many other organizations have also developed guidelines for lung cancer screening.^{12,47-49}

LDCT Screening

Results from the NLST support screening in select individuals who are at high risk for lung cancer.¹¹ Although smoking tobacco is a well-established risk factor for lung cancer, other environmental and genetic factors also increase risk.^{16,17,50-53} Screening with LDCT should only be considered for select high-risk individuals if they are potential candidates for curative-intent therapy. The NCCN panel recommends lung cancer screening for high-risk individuals but not for moderate-risk and low-risk individuals (see LCS-1, page 25).

Selection of Individuals for Lung Screening Based on High-Risk Status

Current or past history of tobacco smoking is the biggest risk factor for the development of lung cancer. In the NCCN Guidelines, current and former smokers aged 55 to 74 years with a 30 or more pack-year history of smoking tobacco are selected as the highest-risk group for lung cancer and are recommended for screening (category 1) based on criteria for entry into the NLST (see LCS-1, page 25).^{11,33} Former smokers with a 30 pack-year smoking history who quit smoking less than 15 years ago are also included in this highest-risk group (category 1). Data for determining whether individuals are at high risk for cancer are based on cigarette smoking and not on other kinds of tobacco products that may also put individuals at risk for cancer. Other risk factors for lung cancer include occupational exposure to carcinogens, radon exposure, cancer history, history of

Lung Cancer Screening, Version 1.2015

lung disease, and family history of lung cancer (see LCS-1, page 25).^{16,50,51}

The NCCN panel recommends lung cancer screening using LDCT for individuals with high-risk factors; 2 groups of individuals qualify as high risk (see LCS-1, page 25):

- Group 1: Aged 55 to 74 years; 30 or more pack-year history of smoking tobacco; and currently smoke or, if former smoker, have quit within 15 years (category 1).^{11,33} This is a category 1 recommendation, because these individuals are selected based on the NLST inclusion criteria.^{11,33} An NCCN category 1 recommendation is based on high-level evidence (ie, randomized controlled trial) and uniform consensus ($\geq 85\%$) among panel members. Annual screening is recommended for these high-risk individuals for 2 years (category 1) based on the NLST.¹¹ Annual screening is recommended until the individual is no longer eligible for definitive treatment (category 2A). Uncertainty exists about the appropriate duration of screening and the age at which screening is no longer appropriate.
- Group 2: Aged 50 years or older, 20 or more pack-year history of smoking tobacco, and one additional risk factor (other than second-hand smoke) (category 2A). This is a category 2A recommendation, because these individuals are selected based on lower level evidence, such as nonrandomized studies, observational data, and ongoing randomized trials.^{40,54-60} Most panel members ($\geq 85\%$) would recommend LDCT for these individuals.⁶¹ Additional risk factors include cancer history, lung disease history, family history of lung cancer, radon exposure, and occupational exposure to carcinogens.^{16,50,51,53,62-65}

The NCCN panel does not believe that exposure to secondhand smoke is an independent risk factor, because the data are either weak or variable.

In the NCCN Guidelines, the age range for LDCT was extended for individuals in the high-risk group 2 for several reasons. The NCCN panel feels that individuals in group 2 are also at high risk for lung cancer based on data from the NLST and other studies as discussed later. NCCN panel members feel

that limitation to the NLST criteria alone is arbitrary and naïve, because the NLST used only age and smoking history for inclusion criteria and did not consider other well-known risk factors for lung cancer. Others share this opinion.^{48,66} Three ongoing phase III randomized trials are screening younger individuals aged 50 to 55 years and older individuals up to 70 to 75 years. The NELSON and UKLS trials are assessing LDCT in individuals 50 to 75 years of age.^{34,35,37,40} The Danish Lung Cancer Screening Trial (DLCST) is screening individuals 50 to 70 years of age.^{54,67} Several studies have assessed LDCT using an extended age range of 50 to 85 years.⁶⁸⁻⁷⁰

For the 2015 update, the NCCN panel unanimously voted to revise the recommendation from category 2B to 2A for individuals aged 50 years or older with a 20 or more pack-year smoking history and 1 additional risk factor (other than second-hand smoke) (see LCS-1, page 25).¹⁵ In earlier versions of the NCCN Guidelines, the panel recommended consideration of screening for this group, but without uniform consensus. The panel feels that it is important to expand screening beyond the NLST criteria to a larger group of at-risk individuals.^{15,71} Using just the narrow NLST criteria, shown in group 1 of the NCCN high-risk category (eg, individuals aged 55-74 years with a ≥ 30 pack-year smoking history), only 27% of patients currently being diagnosed with lung cancer will be covered.⁷¹ A study reported that expanding the high-risk groups eligible for screening, for example including individuals aged 50 or more years with a 20 or more pack-year smoking history and 1 additional risk factor (other than second-hand smoke), may save thousands of additional lives.¹⁵

Age Cutoff and Duration of Screening

What the age cutoff should be at which screening is no longer appropriate is uncertain.⁴⁶ The NCCN Guidelines acknowledge that select high-risk individuals older than 74 years are also eligible for LDCT. At diagnosis of lung cancer, the median age of patients is 70 years.⁵ Approximately 53% of lung cancer is diagnosed in patients aged 55 to 74 years, and approximately 28% is diagnosed in older patients aged 75 to 84 years⁵; screening may benefit the latter population.⁷² The USPSTF recommends LDCT for individuals aged 55 to 80 years.⁴¹ Similarly, the American Association for Thoracic Surgery (AATS) recommends LDCT for individuals aged 55 to 79 years who are high risk.⁴⁸ In addition, data from

Lung Cancer Screening, Version 1.2015

modeling studies suggest that the most advantageous age range for screening is 55 to 80 years old.⁷³ Thus, annual LDCT seems reasonable for select individuals who are high risk and older than 74 years and are eligible for definitive treatment, generally defined as curative intent therapy, including surgery, chemotherapy, and stereotactic body radiation therapy (SBRT) (also known as *stereotactic ablative radiotherapy* [SABR]).

In patients with negative LDCT scans or those whose nodules do not meet the size cutoff for more frequent scanning or other intervention, the NCCN Guidelines recommend considering annual LDCT until individuals are no longer eligible for definitive treatment (see the complete version of these guidelines at NCCN.org). Uncertainty exists about the appropriate duration of screening.⁴⁶ After the 3 rounds of LDCT in the NLST, new cases (n=367) of lung cancer were frequently diagnosed during the 3.5 years of follow-up (median, 6.5 years).^{11,74} The NLST data show that lung cancer continues to occur over time in individuals who are high risk. The incidence of and death rate from lung cancer did not change during the 7 years of the NLST.⁷⁵ Thus, the NLST data support annual LDCT for at least 2 years but do not define a time limit on efficacy.

Management of Nodules Found on LDCT

As shown in the algorithm, LDCT is recommended for detecting noncalcified nodules that may be suspicious for lung cancer depending on their type and size (see the complete version of the NCCN Guidelines for Lung Cancer Screening at NCCN.org).^{76,77} Most noncalcified nodules are solid.³² Solid and subsolid nodules are the 2 main types of pulmonary nodules. Subsolid nodules include nonsolid nodules, also known as *ground glass opacities* or *ground glass nodules*, and part-solid nodules, which contain both ground glass and solid components.^{78–81} Nonsolid nodules are mainly adenocarcinoma in situ or minimally invasive adenocarcinoma, formerly known as *bronchioloalveolar carcinomas*. Patients have a 5-year disease-free survival rate of 100% if completely resected.^{78–80,82–84} Data suggest that many nonsolid nodules resolve, and most that persist may not progress to clinically significant cancer.^{32,77} Solid and part-solid nodules are more likely to be invasive, faster-growing cancers, factors that are reflected in the increased suspicion and follow-up of these nodules.^{79,85–88}

The NCCN recommendations are an adaptation of the Fleischner Society guidelines for solid and subsolid nodules, NLST data, and the International Early Lung Cancer Action Program (IELCAP) protocol guidelines (<http://www.ielcap.org/protocols>).^{79,88} Studies suggested that the definition of a positive result from an LDCT scan should be revised, because the original definition from the NLST was associated with a high percentage of false-positive results.^{11,89–91} Thus, the cutoff sizes for assessing lung nodules currently recommended by NCCN and the American College of Radiology (ACR) have been increased to 6 mm rather than the 4 mm originally used in the NLST and earlier versions of the NCCN Guidelines for Lung Cancer Screening.¹³

The NCCN-recommended cutoff sizes for solid and subsolid nodules detected on LDCT scans are shown in the algorithm (see the complete version of the guidelines at NCCN.org). For nodules that are immediately suspicious for malignancy, diagnostic procedures and/or surgical excision is recommended. For nodules of borderline concern, assessment with interval LDCT scans is often recommended to determine whether the nodule is changing to a suspicious form by increasing in size and/or having a new or growing solid component. For solid or part-solid nodules, the NCCN definition of a positive scan is a solid nodule measuring 6 mm; nodules of this size require a short-term follow-up LDCT scan in 3 months to assess for malignancy.^{7,34,85,92} For nonsolid lesions, the NCCN-recommended cutoff is greater than 5 mm; nodules of this size require a short-term follow-up LDCT scan in 6 months to assess for malignancy. NCCN Guidelines emphasize that nonsolid lesions must be evaluated using thin slices (<1.5 mm) to increase the sensitivity for a solid component and to detect subtle changes over time.^{78,79,93–95}

The ACR has developed the Lung Imaging Reporting and Data System (Lung-RADS) to standardize the reporting and management from LDCT lung examinations.¹⁶ The use of Lung-RADS has been reported to decrease false-positive results.^{16,89,96} The NCCN panel is working to harmonize the NCCN Guidelines for Lung Cancer Screening with Lung-RADS.

LDCT Technical Parameters

Multidetector CT (MDCT) has made it possible to detect and better characterize small lung nodules using fast single-breath-hold acquisitions of the entire

Lung Cancer Screening, Version 1.2015

lungs and by acquiring thinner slices. The use of maximum-intensity projection (MIP) or volume-rendered (VR) image reconstructions and computer-aided diagnosis (CAD) software has increased the sensitivity for detecting small nodules.^{93–95,97–104} For lung cancer screening, LDCT without intravenous contrast is currently recommended, which substantially decreases radiation exposure compared with standard diagnostic chest CTs. LDCT has been shown to be as accurate as standard-dose CT for detecting solid pulmonary nodules, although nodule detection with LDCT may be limited in larger individuals.^{105,106} LDCT may be less sensitive for detecting very low-density nonsolid nodules.¹⁰⁷ Decreasing the radiation dose does not significantly affect the measurement of nodule size when using 1-mm-thick slices.¹⁰⁸

The recommended LDCT acquisition parameters in the NCCN Guidelines are similar to many of the lung cancer screening studies using LDCT. For the 2015 update, the table on LDCT acquisition parameters was moved from the discussion text to the algorithm to increase awareness of this important information (see LCS-A, page 26). Measurement and evaluation of small nodules are more accurate and consistent on 1-mm CT images compared with 5-mm images.⁹³ There may be a similar but less-pronounced benefit in evaluating nodules on 1-mm reconstructed images after detecting them on 2.5- to 3.0-mm slices.

For the 2015 update, the preferred slice width was revised to 1.0 mm or less (from ≤ 1.5 mm) and the acceptable slice width was revised to 2.5 mm or less (from ≤ 3.0 mm) based on Lung-RADS (see LCS-A, page 26).^{16,79,95} Nonsolid lesions must be evaluated at thin slices (< 1.5 mm) to exclude solid components.⁷⁹ Part-solid nodules have a higher malignancy rate than either solid nodules or pure nonsolid nodules and, therefore, require rigorous evaluation.⁷⁹ Because slice thickness, reconstruction algorithms, and post-processing filters affect nodule size measurement, the same technical parameters should be used for each screening LDCT (eg, the same window/width and window/level settings).^{109,110} Some organizations, including the ACR, recommend using CT dose tracking for all CT screening programs to ensure that screening facilities adhere to acceptable low-dose radiation limits (eg, reporting the dose-length product and/or CT dose index for each CT).¹¹¹

LDCT as Part of a Screening Program

Lung cancer screening with LDCT should be part of a program of care and should not be performed

in isolation as a freestanding test.^{112,113} Trained personnel and an organized administrative system for contacting individuals to achieve compliance with recommended follow-up studies are required for an effective lung screening program.¹¹² NCCN-recommended follow-up intervals for LDCT assume compliance with follow-up recommendations. To help ensure good image quality, all LDCT screening programs should use CT scanners that meet quality standards equivalent to or exceeding the accreditation standards of the ACR. Lung-RADS has been shown to improve the detection of lung cancer and decrease the false-positive rate to approximately 1 in 10 screened individuals compared with more than 1 in 4 in NLST.^{16,96,112}

Benefits and Risks of Screening

The goal of screening is to identify disease at an early stage while it is still treatable and curable. The potential huge benefits of lung cancer screening include a reduction in mortality and an improvement in quality of life.^{114,115} Risks of lung screening include false-negative and false-positive results, radiation exposure, overdiagnosis of incidental findings, futile detection of aggressive disease, anxiety, unnecessary testing, complications from diagnostic work-up, and financial costs.^{115–119} Most lung nodules found on LDCT are benign; if possible, these nodules should be assessed using noninvasive procedures to avoid the morbidity of invasive procedures in patients who may not have cancer.^{77,117}

Shared Decision-Making

Because of the high percentage of false-positive results and the downstream management that ensues for many individuals, the risks and benefits of lung cancer screening should be discussed before a screening LDCT scan is performed.^{73,89,114,120–122} Shared patient/physician decision-making may be the best approach before deciding whether to perform LDCT lung screening, especially for patients with comorbid conditions (see LCS-1, page 25).^{41–43} Smoking cessation counseling is recommended.¹²³ Lung screening is not recommended for individuals who are not able or willing to have curative therapy because of health problems or other major concerns.⁴¹ Institutions performing lung cancer screening should use a multidisciplinary approach that may include specialties, such as chest radiology, pulmonary medicine, and thoracic surgery.¹²⁴

Lung Cancer Screening, Version 1.2015

Summary

These NCCN Guidelines Insights focus on some of the major updates to the 2015 NCCN Guidelines for Lung Cancer Screening. The NCCN panel voted to revise the recommendation for LDCT screening from category 2B to 2A for individuals aged 50 years or more with a 20 or more pack-year smoking history and 1 additional risk factor (other than second-hand smoke) (see LCS-1, page 25).¹⁵ This recommendation was revised because the panel feels that it is important to expand screening beyond the NLST criteria to a larger group of at-risk individuals.^{15,71} Using just the narrow NLST criteria, which are individuals aged 55 to 74 years with 30 or more pack-year smoking history, only 27% of patients currently being diagnosed with lung cancer will be covered.⁷¹ Shared decision-making is important when a patient begins a program of annual lung cancer screening, especially for those with comorbid conditions. For LDCT of the lung, the recommended slice width was revised (see LCS-A, page 26). The preferred slice width was revised to 1.0 mm or less (from ≤ 1.5 mm) and the acceptable slice width was revised to 2.5 mm or less (from ≤ 3.0 mm) based on Lung-RADS (see LCS-A, page 26).¹⁶ The table discussing LDCT parameters was moved from the discussion text to the algorithm to increase awareness of this important information (see LCS-A, page 26). The ACR's recently developed Lung-RADS structured reporting and management system seems to improve the detection of lung cancer and decrease the false-positive rate.^{16,96}

References

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. *CA Cancer J Clin* 2014;64:9–29.
2. The Health Consequences of Smoking: A Report of the Surgeon General (ed 2010/07/30). Atlanta: US Department of Health and Human Services; 2004.
3. Thun MJ, Henley SJ, Burns D, et al. Lung cancer death rates in lifelong nonsmokers. *J Natl Cancer Inst* 2006;98:691–699.
4. Jemal A, Bray F, Center MM, et al. Global cancer statistics. *CA Cancer J Clin* 2011;61:69–90.
5. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975–2011, based on November 2013 SEER data submission, posted to the SEER Web site, April 2014. Bethesda, MD: National Cancer Institute; 2014. Available at: http://seer.cancer.gov/csr/1975_2011. Accessed December 10, 2014.
6. Goldstraw P, Crowley J, Chansky K, et al. The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours. *J Thorac Oncol* 2007;2:706–714.
7. Aberle DR, DeMello S, Berg CD, et al. Results of the two incidence screenings in the National Lung Screening Trial. *N Engl J Med* 2013;369:920–931.
8. National Lung Screening Trial Research Team, Church TR, Black WC, et al. Results of initial low-dose computed tomographic screening for lung cancer. *N Engl J Med* 2013;368:1980–1991.
9. Kramer BS, Berg CD, Aberle DR, Prorok PC. Lung cancer screening with low-dose helical CT: results from the National Lung Screening Trial (NLST). *J Med Screen* 2011;18:109–111.
10. Midthun DE. Screening for lung cancer. *Clin Chest Med* 2011;32:659–668.
11. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med* 2011;365:395–409.
12. Detterbeck FC, Mazzone PJ, Naidich DR, Bach PB. Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e78S–92S.
13. Wood DE, Eapen GA, Ettinger DS, et al. Lung cancer screening. *J Natl Compr Canc Netw* 2012;10:240–265.
14. Wood DE. Lung cancer screening: the last 10 years. *J Natl Compr Canc Netw* 2012;10:1323–1325.
15. McKee BJ, Hashim JA, French RJ, et al. Experience with a CT screening program for individuals at high risk for developing lung cancer [published online ahead of print August 28, 2014]. *J Am Coll Radiol*, doi: 10.1016/j.jacr.2014.08.002.
16. Kazerooni EA, Austin JH, Black WC, et al. ACR-STR practice parameter for the performance and reporting of lung cancer screening thoracic computed tomography (CT): 2014 (Resolution 4). *J Thorac Imaging* 2014;29:310–316.
17. Jemal A, Thun MJ, Ries LA, et al. Annual report to the nation on the status of cancer, 1975–2005, featuring trends in lung cancer, tobacco use, and tobacco control. *J Natl Cancer Inst* 2008;100:1672–1694.
18. Centers for Disease Control and Prevention. Current cigarette smoking among adults—United States, 2011. *MMWR Morb Mortal Wkly Rep* 2012;61:889–894.
19. Hecht SS. Tobacco smoke carcinogens and lung cancer. *J Natl Cancer Inst* 1999;91:1194–1210.
20. Secretan B, Straif K, Baan R, et al. A review of human carcinogens—Part E: tobacco, areca nut, alcohol, coal smoke, and salted fish. *Lancet Oncol* 2009;10:1033–1034.
21. Sakoda LC, Loomis MM, Doherty JA, et al. Germ line variation in nucleotide excision repair genes and lung cancer risk in smokers. *Int J Mol Epidemiol Genet* 2012;3:1–17.
22. Centers for Disease Control and Prevention. Smoking-attributable mortality, years of potential life lost, and productivity losses—United States, 2000–2004. *MMWR Morb Mortal Wkly Rep* 2008;57:1226–1228.
23. Jha P, Ramasundarahettige C, Landsman V, et al. 21st-century hazards of smoking and benefits of cessation in the United States. *N Engl J Med* 2013;368:341–350.
24. Doll R, Peto R, Boreham J, Sutherland I. Mortality in relation to smoking: 50 years' observations on male British doctors. *BMJ* 2004;328:1519.
25. Moolgavkar SH, Holford TR, Levy DT, et al. Impact of reduced tobacco smoking on lung cancer mortality in the United States during 1975–2000. *J Natl Cancer Inst* 2012;104:541–548.
26. Peto R, Darby S, Deo H, et al. Smoking, smoking cessation, and lung cancer in the UK since 1950: combination of national statistics with two case-control studies. *BMJ* 2000;321:323–329.
27. Sitas F, Weber MF, Egger S, et al. Smoking cessation after cancer. *J Clin Oncol* 2014;32:3593–3595.
28. Taylor KL, Cox LS, Zincke N, et al. Lung cancer screening as a teachable moment for smoking cessation. *Lung Cancer* 2007;56:125–134.
29. Hays JT, McFadden DD, Ebbert JO. Pharmacologic agents for tobacco dependence treatment: 2011 update. *Curr Atheroscler Rep* 2012;14:85–92.
30. Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e61S–77S.
31. Hulka BS. Cancer screening. Degrees of proof and practical application. *Cancer* 1988;62:1776–1780.
32. Marshall HM, Bowman RV, Yang IA, et al. Screening for lung cancer with low-dose computed tomography: a review of current status. *J Thorac Dis* 2013;5(Suppl 5):S524–539.
33. National Lung Screening Trial Research Team, Aberle DR, Berg CD, et al. The National Lung Screening Trial: overview and study design. *Radiology* 2011;258:243–253.

Lung Cancer Screening, Version 1.2015

34. Horeweg N, van der Aalst CM, Thunnissen E, et al. Characteristics of lung cancers detected by computer tomography screening in the randomized NELSON trial. *Am J Respir Crit Care Med* 2013;187:848–854.
35. McRonald FE, Yadegarfar G, Baldwin DR, et al. The UK Lung Screen (UKLS): demographic profile of first 88,897 approaches provides recommendations for population screening. *Cancer Prev Res (Phila)* 2014;7:362–371.
36. Field JK, van Klaveren R, Pedersen JH, et al. European randomized lung cancer screening trials: post NLST. *J Surg Oncol* 2013;108:280–286.
37. Ru Zhao Y, Xie X, de Koning HJ, et al. NELSON lung cancer screening study. *Cancer Imaging* 2011;11:S79–84.
38. Xu DM, Gietema H, de Koning H, et al. Nodule management protocol of the NELSON randomised lung cancer screening trial. *Lung Cancer* 2006;54:177–184.
39. Nair A, Hansell DM. European and North American lung cancer screening experience and implications for pulmonary nodule management. *Eur Radiol* 2011;21:2445–2454.
40. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). *Int J Cancer* 2007;120:868–874.
41. Moyer VA, Force USPST. Screening for lung cancer: U.S. Preventive Services Task Force recommendation statement. *Ann Intern Med* 2014;160:330–338.
42. Sox HC. Implementing lung cancer screening under Medicare: the last chance to get it right? *JAMA* 2014;312:1206–1207.
43. Volk RJ, Hawk E, Bevers TB. Should CMS cover lung cancer screening for the fully informed patient? *JAMA* 2014;312:1193–1194.
44. Goldberg P. Does a B from USPSTF guarantee coverage? Lung screening will define Medicare stance. *Cancer Letter* 2014;40:1–8.
45. Black WC, Gareen IF, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. *N Engl J Med* 2014;371:1793–1802.
46. Bach PB, Mirkin JN, Oliver TK, et al. Benefits and harms of CT screening for lung cancer: a systematic review. *JAMA* 2012;307:2418–2429.
47. Wender R, Fontham ET, Barrera E Jr, et al. American Cancer Society lung cancer screening guidelines. *CA Cancer J Clin* 2013;63:107–117.
48. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. *J Thorac Cardiovasc Surg* 2012;144:33–38.
49. Roberts H, Walker-Dilks C, Sivjee K, et al. Screening high-risk populations for lung cancer: guideline recommendations. *J Thorac Oncol* 2013;8:1232–1237.
50. Alberg AJ, Brock MV, Ford JG, et al. Epidemiology of lung cancer: Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e1S–29S.
51. Driscoll T, Nelson DI, Steenland K, et al. The global burden of disease due to occupational carcinogens. *Am J Ind Med* 2005;48:419–431.
52. de Groot P, Munden RE. Lung cancer epidemiology, risk factors, and prevention. *Radiol Clin North Am* 2012;50:863–876.
53. Youlden DR, Cramb SM, Baade PD. The International Epidemiology of Lung Cancer: geographical distribution and secular trends. *J Thorac Oncol* 2008;3:819–831.
54. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after five annual screening rounds with low-dose CT. *Thorax* 2012;67:296–301.
55. Tammemagi CM, Pinsky PF, Caporaso NE, et al. Lung cancer risk prediction: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial models and validation. *J Natl Cancer Inst* 2011;103:1058–1068.
56. Spitz MR, Hong WK, Amos CI, et al. A risk model for prediction of lung cancer. *J Natl Cancer Inst* 2007;99:715–726.
57. Cassidy A, Myles JP, van Tongeren M, et al. The LLP risk model: an individual risk prediction model for lung cancer. *Br J Cancer* 2008;98:270–276.
58. Cronin KA, Gail MH, Zou Z, et al. Validation of a model of lung cancer risk prediction among smokers. *J Natl Cancer Inst* 2006;98:637–640.
59. Bach PB, Kattan MW, Thornquist MD, et al. Variations in lung cancer risk among smokers. *J Natl Cancer Inst* 2003;95:470–478.
60. International Early Lung Cancer Action Program Investigators, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I lung cancer detected on CT screening. *N Engl J Med* 2006;355:1763–1771.
61. Bach PB, Gould MK. When the average applies to no one: personalized decision making about potential benefits of lung cancer screening. *Ann Intern Med* 2012;157:571–573.
62. Darby S, Hill D, Auvinen A, et al. Radon in homes and risk of lung cancer: collaborative analysis of individual data from 13 European case-control studies. *BMJ* 2005;330:223.
63. Travis LB, Gospodarowicz M, Curtis RE, et al. Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. *J Natl Cancer Inst* 2002;94:182–192.
64. Matakidou A, Eisen T, Houlston RS. Systematic review of the relationship between family history and lung cancer risk. *Br J Cancer* 2005;93:825–833.
65. Koshiol J, Rotunno M, Consonni D, et al. Chronic obstructive pulmonary disease and altered risk of lung cancer in a population-based case-control study. *PLoS One* 2009;4:e7380.
66. Berg CD. Formidable challenges ahead for lung cancer screening. *Oncology (Williston Park)* 2012;26:182, 185.
67. Pedersen JH, Ashraf H, Dirksen A, et al. The Danish randomized lung cancer CT screening trial—overall design and results of the prevalence round. *J Thorac Oncol* 2009;4:608–614.
68. Menezes RJ, Roberts HC, Paul NS, et al. Lung cancer screening using low-dose computed tomography in at-risk individuals: the Toronto experience. *Lung Cancer* 2010;67:177–183.
69. Swensen SJ, Jett JR, Hartman TE, et al. CT screening for lung cancer: five-year prospective experience. *Radiology* 2005;235:259–265.
70. Wilson DO, Weissfeld JL, Fuhrman CR, et al. The Pittsburgh Lung Screening Study (PLuSS): outcomes within 3 years of a first computed tomography scan. *Am J Respir Crit Care Med* 2008;178:956–961.
71. Pinsky PF, Berg CD. Applying the National Lung Screening Trial eligibility criteria to the US population: what percent of the population and of incident lung cancers would be covered? *J Med Screen* 2012;19:154–156.
72. Varlotto JM, Decamp MM, Flickinger JC, et al. Would screening for lung cancer benefit 75- to 84-year-old residents of the United States? *Front Oncol* 2014;4:37.
73. de Koning HJ, Meza R, Plevritis SK, et al. Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. *Ann Intern Med* 2014;160:311–320.
74. Sox HC. Better evidence about screening for lung cancer. *N Engl J Med* 2011;365:455–457.
75. Jett JR, Midthun DE. Screening for lung cancer: for patients at increased risk for lung cancer, it works. *Ann Intern Med* 2011;155:540–542.
76. Truong MT, Ko JP, Rossi SE, et al. Update in the evaluation of the solitary pulmonary nodule. *Radiographics* 2014;34:1658–1679.
77. Brawley OW, Flanagan EL. Low-dose spiral CT screening and evaluation of the solitary pulmonary nodule. *Oncology (Williston Park)* 2014;28:441–446.
78. Gardiner N, Jogai S, Wallis A. The revised lung adenocarcinoma classification—an imaging guide. *J Thorac Dis* 2014;6:S537–546.
79. Naidich DP, Bankier AA, MacMahon H, et al. Recommendations for the management of subsolid pulmonary nodules detected at CT: a statement from the Fleischner Society. *Radiology* 2013;266:304–317.
80. Seidelman JL, Myers JL, Quint LE. Incidental, subsolid pulmonary nodules at CT: etiology and management. *Cancer Imaging* 2013;13:365–373.
81. Hansell DM, Bankier AA, MacMahon H, et al. Fleischner Society: glossary of terms for thoracic imaging. *Radiology* 2008;246:697–722.
82. Travis WD, Brambilla E, Noguchi M, et al. Diagnosis of lung cancer in small biopsies and cytology: implications of the 2011 International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society classification. *Arch Pathol Lab Med* 2013;137:668–684.
83. Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/american thoracic society/european respiratory society international multidisciplinary classification of lung adenocarcinoma. *J Thorac Oncol* 2011;6:244–285.
84. Kim HY, Shim YM, Lee KS, et al. Persistent pulmonary nodular ground-glass opacity at thin-section CT: histopathologic comparisons. *Radiology* 2007;245:267–275.
85. Gould MK, Donington J, Lynch WR, et al. Evaluation of individuals with pulmonary nodules: when is it lung cancer? Diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. *Chest* 2013;143:e93S–120S.

Lung Cancer Screening, Version 1.2015

86. Chang B, Hwang JH, Choi YH, et al. Natural history of pure ground-glass opacity lung nodules detected by low-dose CT scan. *Chest* 2013;143:172–178.
87. Lindell RM, Hartman TE, Swensen SJ, et al. Five-year lung cancer screening experience: CT appearance, growth rate, location, and histologic features of 61 lung cancers. *Radiology* 2007;242:555–562.
88. MacMahon H, Austin JH, Gamsu G, et al. Guidelines for management of small pulmonary nodules detected on CT scans: a statement from the Fleischner Society. *Radiology* 2005;237:395–400.
89. Gierada DS, Pinsky P, Nath H, et al. Projected outcomes using different nodule sizes to define a positive CT lung cancer screening examination. *J Natl Cancer Inst* 2014;106.
90. Yip R, Henschke CI, Yankelevitz DF, Smith JP. CT screening for lung cancer: alternative definitions of positive test result based on the National Lung Screening Trial and International Early Lung Cancer Action Program databases. *Radiology* 2014;273:591–596.
91. Horeweg N, van Rosmalen J, Heuvelmans MA, et al. Lung cancer probability in patients with CT-detected pulmonary nodules: a prespecified analysis of data from the NELSON trial of low-dose CT screening. *Lancet Oncol* 2014;15:1332–1341.
92. Henschke CI, Yip R, Yankelevitz DF, et al. Definition of a positive test result in computed tomography screening for lung cancer: a cohort study. *Ann Intern Med* 2013;158:246–252.
93. Lee HY, Goo JM, Lee HJ, et al. Usefulness of concurrent reading using thin-section and thick-section CT images in subcentimetre solitary pulmonary nodules. *Clin Radiol* 2009;64:127–132.
94. Fischbach F, Knollmann F, Griesshaber V, et al. Detection of pulmonary nodules by multislice computed tomography: improved detection rate with reduced slice thickness. *Eur Radiol* 2003;13:2378–2383.
95. Valencia R, Denecke T, Lehmkuhl L, et al. Value of axial and coronal maximum intensity projection (MIP) images in the detection of pulmonary nodules by multislice spiral CT: comparison with axial 1-mm and 5-mm slices. *Eur Radiol* 2006;16:325–332.
96. McKee BJ, Regis SM, McKee AB, et al. Performance of ACR Lung-RADS in a clinical CT lung screening program [published online ahead of print August 28, 2014]. *J Am Coll Radiol*, doi: 10.1016/j.jacr.2014.08.004.
97. Kawel N, Seifert B, Luetolf M, Boehm T. Effect of slab thickness on the CT detection of pulmonary nodules: use of sliding thin-slab maximum intensity projection and volume rendering. *AJR Am J Roentgenol* 2009;192:1324–1329.
98. Peloschek P, Sailer J, Weber M, et al. Pulmonary nodules: sensitivity of maximum intensity projection versus that of volume rendering of 3D multidetector CT data. *Radiology* 2007;243:561–569.
99. Park EA, Goo JM, Lee JW, et al. Efficacy of computer-aided detection system and thin-slab maximum intensity projection technique in the detection of pulmonary nodules in patients with resected metastases. *Invest Radiol* 2009;44:105–113.
100. Jankowski A, Martinelli T, Timsit JF, et al. Pulmonary nodule detection on MDCT images: evaluation of diagnostic performance using thin axial images, maximum intensity projections, and computer-assisted detection. *Eur Radiol* 2007;17:3148–3156.
101. Rubin GD, Lyo JK, Paik DS, et al. Pulmonary nodules on multi-detector row CT scans: performance comparison of radiologists and computer-aided detection. *Radiology* 2005;234:274–283.
102. Fraioli F, Bertoletti L, Napoli A, et al. Computer-aided detection (CAD) in lung cancer screening at chest MDCT: ROC analysis of CAD versus radiologist performance. *J Thorac Imaging* 2007;22:241–246.
103. Sahiner B, Chan HP, Hadjiiski LM, et al. Effect of CAD on radiologists' detection of lung nodules on thoracic CT scans: analysis of an observer performance study by nodule size. *Acad Radiol* 2009;16:1518–1530.
104. Das M, Muhlenbruch G, Heinen S, et al. Performance evaluation of a computer-aided detection algorithm for solid pulmonary nodules in low-dose and standard-dose MDCT chest examinations and its influence on radiologists. *Br J Radiol* 2008;81:841–847.
105. Kubo T, Lin PJ, Stiller W, et al. Radiation dose reduction in chest CT: a review. *AJR Am J Roentgenol* 2008;190:335–343.
106. Lee JY, Chung MJ, Yi CA, Lee KS. Ultra-low-dose MDCT of the chest: influence on automated lung nodule detection. *Korean J Radiol* 2008;9:95–101.
107. Funama Y, Awai K, Liu D, et al. Detection of nodules showing ground-glass opacity in the lungs at low-dose multidetector computed tomography: phantom and clinical study. *J Comput Assist Tomogr* 2009;33:49–53.
108. Hein PA, Romano VC, Rogalla P, et al. Linear and volume measurements of pulmonary nodules at different CT dose levels - intrascan and interscan analysis. *Rofu* 2009;181:24–31.
109. Rampinelli C, Origgi D, Bellomi M. Low-dose CT: technique, reading methods and image interpretation. *Cancer Imaging* 2013;12:548–556.
110. Donnelly EF. Technical parameters and interpretive issues in screening computed tomography scans for lung cancer. *J Thorac Imaging* 2012;27:224–229.
111. Christner JA, Kofler JM, McCollough CH. Estimating effective dose for CT using dose-length product compared with using organ doses: consequences of adopting International Commission on Radiological Protection publication 103 or dual-energy scanning. *AJR Am J Roentgenol* 2010;194:881–889.
112. Mazzone P, Powell CA, Arenberg D, et al. Components necessary for high quality lung cancer screening: American College of Chest Physicians and American Thoracic Society Policy Statement [published online ahead of print October 30, 2014]. *Chest*, doi: 10.1378/chest.14-2500.
113. Davis AM, Cifu AS. Lung cancer screening. *JAMA* 2014;312:1248–1249.
114. Aberle DR, Abtin F, Brown K. Computed tomography screening for lung cancer: has it finally arrived? Implications of the national lung screening trial. *J Clin Oncol* 2013;31:1002–1008.
115. Dettlerbeck FC. Overdiagnosis during lung cancer screening: is it an overemphasised, underappreciated, or tangential issue? *Thorax* 2014;69:407–408.
116. Wiener RS. Balancing the benefits and harms of low-dose computed tomography screening for lung cancer: Medicare's options for coverage. *Ann Intern Med* 2014;161:445–446.
117. Ettinger DS. Lung cancer screening: has its time come? *Oncology (Williston Park)* 2014;28:342, 448.
118. Braillon A. Bronchioalveolar lung cancer: screening and overdiagnosis. *J Clin Oncol* 2014;32:3575.
119. Johnson DH, Schiller JH, Bunn PA. Reply to A. Braillon. *J Clin Oncol* 2014;32:3575.
120. Woloshin S, Schwartz LM, Black WC, Kramer BS. Cancer screening campaigns—getting past uninformative persuasion. *N Engl J Med* 2012;367:1677–1679.
121. Wiener RS, Gould MK, Woloshin S, et al. What do you mean, a spot?: a qualitative analysis of patients' reactions to discussions with their physicians about pulmonary nodules. *Chest* 2013;143:672–677.
122. Goulart BH, Ramsey SD. Moving beyond the national lung screening trial: discussing strategies for implementation of lung cancer screening programs. *Oncologist* 2013;18:941–946.
123. Tammemagi MC, Berg CD, Riley TL, et al. Impact of lung cancer screening results on smoking cessation. *J Natl Cancer Inst* 2014;106:dju084.
124. Field JK, Smith RA, Aberle DR, et al. International Association for the Study of Lung Cancer Computed Tomography Screening Workshop 2011 report. *J Thorac Oncol* 2012;7:10–19.

Lung Cancer Screening, Version 1.2015

Instructions for Completion

To participate in this journal CE activity: 1) review the learning objectives and author disclosures; 2) study the education content; 3) take the posttest with a 66% minimum passing score and complete the evaluation at <http://education.nccn.org/node/59435>; and 4) view/print certificate. After reading the article, you should be able to answer the following multiple-

choice questions. Credit cannot be obtained for tests completed on paper. You must be a registered user on NCCN.org. If you are not registered on NCCN.org, click on "New Member? Sign up here" link on the left hand side of the Web site to register. Only one answer is correct for each question. Once you successfully answer all posttest questions you will be able to view and/or print your certificate. Software requirements: Internet.

Posttest Questions

- Lung cancer screening using LDCT is recommended by the NCCN Guidelines for which of the following individuals?
 - Individuals 55 to 74 years of age who have smoked fewer than 10 packs of cigarettes in their lifetime.
 - Former smokers 55 to 74 years of age who smoked 1 pack of cigarettes/day for less than 10 years, quit smoking more than 15 years ago, and have a family history of lung cancer.
 - Current smokers 55 to 74 years of age who have smoked 2 pack of cigarettes/day for at least 15 years.
 - Former smokers 55 to 74 years of age, who quit less than 15 years ago, but who previously smoked 1 pack of cigarettes/day for at least 30 years.

There is only one correct answer.

 - 1 and 2
 - 2 and 3
 - 3 and 4
 - 2 and 4
- True or False: *Pack years* of smoking history is defined as the number of packs of cigarettes smoked every day multiplied by the number of years of smoking.
- Clinician/patient shared decision-making is an excellent ap-

proach when deciding whether to recommend lung cancer screening using LDCT to individuals determined to be at high risk for lung cancer for which of the following reasons?

- Individuals at high risk need to know that lung screening with LDCT may lead to invasive procedures for a problem that turns out to be benign.
- Individuals at high risk need to know that lung screening with LDCT may result in a diagnosis of advanced lung cancer, which cannot be cured by treatment.
- Individuals at high risk should also be offered other effective lung screening options, such as chest radiography.
- Elderly patients with comorbid conditions who are at high risk because of their smoking history should be persuaded that lung screening with LDCT will not harm them and is very advantageous.

There is only one correct answer.

- 1 and 2
- 2 and 3
- 2 and 4
- 1 and 4

